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Abstract
Purpose The direct cost to the National Health Service
(NHS) in England of pars plana vitrectomy (PPV) is
unknown since a bottom-up costing exercise has not been
undertaken. Healthcare resource group (HRG) costing
relies on a top-down approach. We aimed to quantify the
direct cost of intermediate complexity PPV.
Methods Five NHS vitreoretinal units prospectively
recorded all consumables, equipment and staff salaries
during PPV undertaken for vitreomacular traction,
epiretinal membrane and macular hole. Out-of-surgery
costs between admission and discharge were estimated
using a representative accounting method.
Results The average patient time in theatre for 57 PPVs
was 72 min. The average in-surgery cost for staff was
£297, consumables £619, and equipment £82 (total £997).
The average out-of-surgery costs were £260, including
nursing and medical staff, other consumables, eye drops
and hospitalisation. The total cost was therefore £1634,
including 30 % overheads. This cost estimate was an
under-estimate because it did not include out-of-theatre
consumables or equipment. The average reimbursed HRG
tariff was £1701.
Conclusions The cost of undertaking PPV of intermediate
complexity is likely to be higher than the reimbursed tariff,
except for hospitals with high throughput, where amorti-
sation costs benefit from economies of scale. Although this
research was set in England, the methodology may provide
a useful template for other countries.
Keywords Cost  Macular hole  Epiretinal membrane 
Vitreomacular traction  Pars plana vitrectomy
JEL Classification I1 Health  I19 Other
Introduction
The English National Health Service (NHS) is a govern-
ment-funded body responsible for delivering healthcare to
England’s public. Government funding is channelled
through Clinical Commissioning Groups (CCG). CCGs are
responsible for ensuring that services provided in their
local area meet patients’ needs, NHS standards and costs,
by commissioning NHS hospitals, private sector providers,
charities and social enterprises. Introduced in 2003, Pay-
ment by Results (PbR) underpins healthcare payments for
most hospital care within England’s NHS. PbR sets ‘‘tar-
iffs’’ for a range of interventions. This in turn is defined by
Healthcare Resource Groups (HRGs) codes, which are used
to classify diagnoses (ICD-10 code) and interventions
(OCPS-4). The tariff covers all costs incurred from
admission to discharge of the patient. Tariffs are calculated
based on national average of costs incurred in the last
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3 years within the mandatory reference cost collection
system, adjusted for inflation, efficiency (since
2010–2011), and the Market Force Factor (MFF). The
HRG4 tariffs, implemented in 2009–2010, also account for
co-morbidities, complications, age and length of stay [1].
The objective of PbR was to incentivise improved per-
formance through greater patient choice—payments would
follow patients to whichever hospital they chose to attend
[2]. This system, however, is not without its challenges.
Indeed, the accuracy of the costing data underpinning the
tariffs remains poor for certain providers or individual unit
costs. Progress has been seen since, but a number of issues
remain unresolved [3]. Issues around HRG coding have
also resulted in an underpayment of £60 million pounds for
acute care and in under and over-payments of between
£600 and £700 million for admitted patient care in
2011/2012. Improvements have been seen since the
implementation of the PbR assurance framework in recent
years, but the value of the errors and the variability
amongst providers remain high.
This study seeks to empirically test whether the reim-
bursed HRG tariff for an ophthalmic surgical procedure
called pars plana vitrectomy (PPV) is close to parity with
the real costs incurred in NHS hospitals. PPV is the most
commonly performed vitreoretinal operation, comprising
71 % of all vitreoretinal procedures in the UK [4]. It is
undertaken for a range of indications, but the most com-
mon are retinal detachment, macular hole (MH), epiretinal
membrane (ERM), and diabetic eye disease [4].
Several studies have attempted to estimate the cost of
PPV for a range of conditions [5–13], but only two studies,
both from Germany, undertook a bottom-up costing
approach [14, 15]. They concluded that the reimbursement
for inpatient PPV does not cover the more complex pro-
cedures. Most studies estimated costs based on coverage
tariffs, that is, the costs were based on what was reim-
bursed (Table 1).
The indications for PPV in these costing studies inclu-
ded diabetic retinopathy [10], retinal detachment [5, 6, 8,
11], eye injuries [15], ERM [7, 11], retinopathy of pre-
maturity [9], and endophthalmitis [6, 12, 13]. A number of
cost-effectiveness analyses (CEA) collected reimbursement
cost data in the US, and used these figures to populate CEA
models [5–7, 9]. The estimated cost of PPV ranged
between £1601 (US $2500) for an outpatient with
endophthalmitis in Florida (US) [12], to £8280
(US $13,000) for a PPV with intravenous antibiotics in
Pennsylvania (US) [13]. The cost of hospitalisation varied
between £884 and £1867 ($1388 and €2184) [10, 15], with
an average duration of 1 week in those requiring admission
[8, 14, 15], but these studies were conducted up to 7 years
ago, or included severe eye diseases such as penetrating
eye injury, and may not be relevant to more representative
cases in 2014–2015. Some studies included the cost of
adjunct interventions associated with PPV such as encir-
cling band, perfluorocarbon liquid, indocyanine green used
as a vital stain, tissue plasminogen activator used to dis-
solve submacular hemorrhage, intravitreal gas or silicone
oil tamponade, or cataract surgery and as such comprised a
heterogeneous mix of cases. In one German study, the
additional cost for these adjunct interventions was esti-
mated between £44 and £214 (€51–250) [14]. Another
German study reported that 90 % of PPVs included one
adjunct intervention, and 50 % included two [15]. One US
study examined hospital costs (including operating room,
post-anaesthesia care unit, pharmacy and anaesthesia) for
patients undergoing PPV with membrane peel with either
local or general anaesthesia, which were found to be £3483
(US $5649) and £4571 (US $7177), respectively [16]. In
addition to the cost of surgery, two US studies reported the
cost of a 30-day follow-up period together with costs of
care for the 1st year [10, 11]. All these studies were per-
formed outside the UK and used coverage rather than
actual costs, based on a top-down costing approach.
The objective of this study was to estimate the actual
direct cost of undertaking PPV of intermediate complexity
in a NHS setting, using a bottom-up approach, and com-
pare it to the actual cost reimbursed under the NHS PbR
system. Differences in estimates suggest that inefficiencies
in the healthcare system exist, including in the incentives
implemented [17]. The advantage of using a bottom-up
rather than a top-down costing approach is that it accounts
for differences in resource use that varies over time and
between individuals, which in turn may explain the cost
items or drivers contributing to these differences in esti-
mates (across hospitals and with the HRG estimates) [17].
This is particularly important for heterogeneous interven-
tions such as for PPV [15]. Three indications were selected
as being representative of a typical intermediate com-
plexity PPV: MH, ERM, and vitreomacular traction
(VMT).
Materials and methods
Five representative, geographically spread, teaching and
non-teaching NHS vitreoretinal units were included in the
study.
The study selected commonly performed PPV inter-
ventions of similar, intermediate complexity (MH, ERM,
VMT) in order to ensure a homogeneous sample [4]. Cases
that required cataract surgery as part of the PPV were not
excluded, to ensure the samples were representative as
studies indicate that cataract surgery is undertaken in
27–41 % of cases [4, 18]. Research ethics committee
review was not required according to UK guidance, as the
E. Nicod et al.
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study was considered to be either a service evaluation or an
economic audit [19].
The direct cost of PPV was estimated based on two sets
of data: in-theatre costs and out-of-theatre costs. The for-
mer was estimated based on all real costs incurred during
surgery, and the latter was estimated using the range of
identifiable costs recorded within the accounting system in
a representative hospital for a cohort of 31 patients with
similar conditions and comprising costs incurred out-of-
theatre between admission and discharge of the patient
(hereafter referred to as the cohort data), as well as an
estimation of nursing and medical staff time before and
after surgery. The out-of-theatre costs included a fixed rate
for the contribution of different staff (pharmacists and
other allied health care professional) as well as clinical,
scientific and diagnostic services (including imaging and
other diagnostic examinations). Out-of-theatre medical and
nursing time were estimated and validated by all partners.
This out-of-theatre costing did not consider consumables
used outside of the operating theatre with the exception of
eye drops, nor did it include other clinical and non-clinical
supplies (e.g. information leaflets) or equipment (e.g.
recovery equipment, cardiorespiratory monitor).
For the in-theatre data collection, standard data collec-
tion templates were created then customised to each site. A
site-initiation visit was conducted by two research associ-
ates (F.G., A.A.) to perform a general inspection of the
operating environment, to provide staff training in data
collection, and to record all capital equipment used for
performing PPV.
All consecutive NHS PPVs under the care of the named
consultant clinical investigator were recorded in a surgical
log. The surgical log recorded the surgical elements, date
and indication for PPV. The log was completed to provide
an estimate of the proportion of PPVs undertaken for the
reference indications. The study period began at each site
following site initiation, on the day the first surgical list
included a case of MH, ERM or VMT. Sites continued to
collect data from consecutive PPVs until the surgical log
included at least 10 cases of either MH, ERM, or VMT, and
also until there was a minimum of 30 PPVs (for any
indication). Data collection ran from March to September
2012. No patient details were recorded other than age and
indication for surgery. An ophthalmologist or ophthalmic
theatre nurse completed the surgical log at the time of
surgery. The investigators and hospital managers were
advised that any cost data they provide would be anon-
ymised by the research team.
Resource utilisation and cost data were collected on the
customised source documents for all PPVs undertaken for
the reference conditions during the study period (Table 2).
The resource utilisation template, completed by either the
ophthalmologist or ophthalmic theatre nurse, collectedT
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information on the length of surgery, the theatre and
anaesthetic staff involved in surgery, and the consumables
used during surgery.
Costing data were divided into six categories: staff;
consumables; equipment; overnight stay; overheads; and
other costs.
In-theatre staff costs were calculated based on the
number of minutes spent by each staff member in theatre,
their position and the median midpoint salary for that band
[20]. Hourly rates were based on a 220-day working year
and 7.5 h working day, resulting in a total of 1650 h per
year. A 10 % national insurance contribution (NIC) and
14 % NHS Scheme Pension employer contribution were
added to base salaries, together with the high cost area
supplement for inner and outer London [20]. For out-of-
theatre nursing staff, we added 15 min pre-operative time
for local anaesthetic patients (25 for general anaesthetic
patients), and 15 min post-operative time (30 for general
anaesthetic patients, with an additional 20 min for the
recovery nurse). For each ophthalmologist, we added 7 min
for each patient to allow for the preoperative ward round,
the time needed to change into surgical scrubs, liaising
with nursing and administrative staff, and unforeseen and
miscellaneous delays, and patients who failed to attend
theatre or were cancelled on the day. For anaesthetic staff
we allowed 4 min per patient.
Consumable costs were based on the purchasing price to
the hospital, less any rebates. Undisclosed costs were esti-
mated based on the average cost of similar items across other
sites. Under ‘‘Other costs’’, out-of-theatre costs relating to
pharmacist staff costs (fixed rate) and diagnostics and lab-
oratory tests (variable rate) were extracted from the cohort
data and merged into one cost item, estimated at £94.10.
Equipment costs were calculated per PPV based on equip-
ment purchasing price (less rebates), yearly maintenance
costs, amortisation period (in years), and number of PPVs
performed per year. An allocation was made for each piece
of capital equipment, based on the percentage time used for
Table 2 Data source and cost calculations
In-theatre bottom-up
Staff Consumables Equipment
Resource use Resource utilisation log: length of
surgery in minutes for all staff
involved
Resource utilisation log: list of all
consumables used for each
surgical intervention
Equipment log: all equipment
routinely used for PPV
Cost estimate NHS salary bands: hourly rate
calculated using median values
(including employer National
Insurance and pension
contribution, and high cost area
supplements)
Cost log: purchasing price to
hospital, accounting for rebates.
Any undisclosed costs (8.5 % of
items for Hospital 2) were
estimated based on the average
cost across other hospitals for the
same items, when available
Equipment log: cost per PPV
estimated using purchasing price
(including rebates), yearly
maintenance costs, amortisation
period and number of operations
per year. When data were
unavailable, cost estimated at
average across other hospitals
Out-of theatre cohort accounting data
Staff Other costs Overnight stay
Resource use Per patient perioperative staff time
was 7 min for ophthalmologists,
4 min for anaesthetists, 15 min
for pre-operative nursing
(25 min if general anaesthetic),
15 min post-operative nursing
(30 min if general anaesthetic
plus 20 min for recovery nurse)
Cohort data: all additional
identifiable out-of-surgery costs.
Information about the eye drops
used before and after surgery
were collected from each site
Surgical log: proportion of patients
with overnight stay, estimated
for each hospital
Cost estimate NHS salary bands: same as for in-
theatre
Cohort data: identifiable costs
relating to pharmacist staff costs
(fixed cost), merged with
diagnostic and laboratory tests
(variable cost). The hospital
purchasing price was used to
estimate the cost of eye drops
NHS HRG reimbursement tariffs
for overnight stays
Other
Overheads: Estimated at 30 % of total costs based on Healthcare Financial Management Association’s (HfMA) clinical costing guidelines
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PPV. For example, if an operating microscope was used half
the time for PPV and half for other operations, it would have
a 50 % cost allocation. When patients stayed overnight, the
HRG reimbursement tariff for an overnight stay (£266 per
night) was estimated pro rata on the average number of days
in hospital, per patient, for each hospital [21].
Overheads were estimated at 30 % of all direct costs
based on published NHS guidelines [22]. These account for
all costs related to the general management of the hospital,
such as costs related to facilities, electricity, general
cleaning, management, or finance and legal staff, and
which are not driven by the level of patient activity.
The direct cost was compared to the actual amount
reimbursed to the hospital for each patient. The reim-
bursement tariff is determined by published HRG inter-
vention codes [1], under the PbR system. The codes used to
classify MH, ERM, VMT and other retinal diagnoses such
as age-related macular degeneration or diabetic macular
oedema are the same, and are categorised by the level of
complexity of the case, from high to low (BZ20Z, BZ21Z,
BZ22Z, BZ23Z), ranging between £1823 and £504. These
differ from NHS Reference Costs used as a benchmark to
calculate the PbR tariffs (£402–£2707).
Consultants completed a questionnaire detailing the
advice they provided to patients in terms of time off work,
and the time required for head posturing following MH
surgery.
Results
A total of 151 PPVs were recorded during the evaluation,
of which 57 (37.7 %) were for the reference conditions. Of
the 57 cases, 24 had MH (42.1 %), 22 ERM (38.6 %), five
VMT (8.8 %), and six had two or more of the reference
conditions (10.5 %). Cataract surgery was performed in 25
cases (43.9 %), and 19 (33.3 %) had an overnight stay. The
mean patient age was 72 years (range 63–89) for MH, 71
(46–93) for ERM and 74 (45–82) for VMT.
The average time spent in-theatre was 72 min (range
58–83), and the average number of theatre health profes-
sionals involved was 6.5 (range 5–8). This comprised one
or two surgeons (such as consultant and fellow), one
anaesthetist (such as consultant or associate specialist), one
anaesthetic assistant, two circulating nurses, and one scrub
nurse. In four of the five sites, all staff allocated 100 % of
their time to the PPV, the fifth site allocated between 75
and 100 % of total staff time as they may have been
assisting outside of the reference theatre. The average
number of consumable items used in-theatre per PPV was
62 (range 35–110), including items used to perform cat-
aract surgery and anaesthesia. The standard equipment
used to perform PPV in all sites (and the allocation made to
PPV surgery) included a vitrectomy machine (93 %),
endolaser (100 %), cryotherapy device (100 %), BIOM
lens system and microscope inverter (100 %), and operat-
ing microscope (58 %).
The average in-theatre staff cost was £296.90 (range
£229.20–£376.70), and the average in-theatre consumables
cost was £618.60 (range £509.65–£715.50), including cost
estimates for undisclosed costs. The average cost of each
equipment item across the four sites was £87,000 for the
vitrectomy machine (range £54,000–£120,000), £105,881
for the operating microscope (range £90,284–£126,000),
£25,800 for the endolaser (range £10,800–£40,800),
£32,654 for the BIOM (range £29,751–£38,210), and £8664
for the cryotherapy machine (range £3613–£13,738). The
mean equipment cost per PPV, dividing the yearly cost by
the number of PPVs performed per year, was £81.75 (range
£47.80–£150.30), with average yearly maintenance costs of
£1822.80 (range £880.00–£2555.60), average amortisation
period of 8.9 years (range 7.0–10.5), and average annual
number of PPVs per machine of 478 (range 225–750).
The estimated average in-theatre cost of PPV was
£997.20 (range £825.45–£1166.10), comprising £296.90
for staff, £618.60 for consumables, and £81.70 for capital
surgical equipment.
Out-of-theatre costs were estimated as £70.65 (range
£55.10–£91.20) for nursing and medical staff costs, £86.90
(range £0.00–£177.35) for hospitalisation and £102.40
(range £99.25–£109.33) for other costs, including eye
drops (Table 3).
The direct cost of PPV, including both in-theatre and
out-of-theatre costs, was £1257.10, which increased to
£1634.25 once the 30 % overhead was included.
Reimbursement was at the highest HRG tariff (BZ20Z,
£1823 without the MFF uplift, that accounts for unavoid-
able cost differences of providing healthcare [23]) in 18
cases (32 %), second highest (BZ21Z, £1439) in 34 (60 %)
and third highest (BZ22Z, £1013) in 4 (7 %; three of which
were coded erroneously as anterior vitrectomy). None were
reimbursed under the lowest tariff (BZ23Z, £504) and one
phakovitrectomy case was reimbursed erroneously under
the cataract tariff (BZ02Z, £704) without consideration of
the PPV. The average HRG tariff effectively reimbursed
across the 57 cases was £1701.20 including the MFF uplift.
When comparing the real costs incurred with the amounts
reimbursed, 38.6 % of the 57 cases incurred higher costs than
their reimbursement (Fig. 1). This was 11.1 % of cases in the
highest HRG tariff group (BZ20Z), 44.1 % of 34 cases in the
second highest HRG tariff group (BZ21Z) and 100 % of 4
cases in the third tariff group (BZ22Z). There were moder-
ately large variations in the in-theatre costs across the five
hospitals: 39.2 % for staff (range £229.20–£376.70), 68.2 %
for equipment (range £47.80–£150.30) and 28.8 % for con-
sumable costs (range £509.70–£715.50).
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Consultants advised between 1 and 4 weeks off work
depending on the patient’s occupation (mean 2.16 weeks).
Post-operative face down head posturing was advised fol-
lowing MH surgery by all consultants, with the advised
duration of posturing ranging from 1 to 7 days (mean
3.87 days, median 4 days).
Discussion
The average cost of performing PPV was estimated to be
£1634.25 including overheads (range £1379.55–£1787.15);
the average amount reimbursed to the hospitals under the
HRG PbR scheme was £1701. Although this finding
suggests that the cost incurred by hospitals is close to the
reimbursed tariff with a relative difference of 4.1 %, our
cost is likely to underestimate the true cost as it did not
account for a range of costs incurred outside of the oper-
ating room, such as other clinical and non-clinical supplies
(e.g. information leaflets) or equipment (e.g. recovery
equipment, cardiorespiratory monitor).
The shortfall between hospital costs and reimbursement
was most marked for cases coded under the middle tariffs
(44.1 % of 34 cases under BZ21Z tariff and 100 % of 4
cases under BZ22Z tariff), suggesting that the reimburse-
ment may be insufficient, or that the codes are incorrectly
applied given that cases with peeling should have been
coded under BZ21Z and not BZ22Z. Coding was
Table 3 Average estimated cost of PPV for ERM, VMT and MH in 5 UK Hospitals. ERM Epiretinal membrane, MH macular hole, PPV pars
plana vitrectomy, VMT vitreomacular traction
Staff (in-theatre
and out-of-theatre)
Consumables Equipment Other costs
(including eye
drops)
Overnight
stay
Total
direct
cost
Overhead
(30 %)
Total (including
overheads)
Hospital 1 £422.23 £509.66 £150.28 £109.33 £0.00 £1191.51 £357.45 £1548.96
Hospital 2 £340.07 £675.37 £81.70 £100.24 £177.33 £1374.72 £412.41 £1787.13
Hospital 3 £284.31 £548.47 £47.77 £100.83 £79.80 £1061.18 £318.35 £1379.53
Hospital 4 £346.34 £643.79 £54.87 £99.25 £177.33 £1321.58 £396.47 £1718.06
Hospital 5 £444.73 £715.48 £73.88 £102.41 £0.00 £1336.51 £400.95 £1737.46
Average £367.54 £618.56 £81.70 £102.41 £86.89 £1257.10 £377.13 £1634.23
Figure 1 Proportion of cases reimbursed at less than the real costs
incurred. The reimbursed cost is compared with the actual costs
incurred for all cases and per healthcare resource group (HRG) tariff
category; 38.6 % of 57 cases incurred higher costs than their
reimbursement. This was 11.1 % of 18 cases in the highest HRG
tariff group (BZ20Z), 44.1 % of 34 cases in the second highest group
(BZ21Z) and 100 % of 4 cases in the third tariff group (BZ22Z)
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sometimes inconsistent, with the same procedures attract-
ing different reimbursement depending on how the proce-
dure was coded. In addition, one case was erroneously
coded as a cataract operation, with no payment for PPV,
resulting in a shortfall of £947, and three were erroneously
coded as anterior vitrectomy, with a shortfall of £436 each.
There was considerable variation in the discrepancy
between cost and reimbursement when comparing different
hospitals. One of the main drivers for this difference was
based on economies of scale. For example, the higher
equipment cost in Hospital 1 can be attributed to the lower
number of PPVs performed there, estimated at 250 per
year. Other hospitals ranged from 400 and 750 cases
annually, which is associated with a lower amortisation
cost.
This study did not assess the indirect costs of PPV
relating to productivity losses, the burden of surgery,
recovery time or lay care. These costs were considered
beyond the scope of this study, which aimed primarily to
compare the cost-benefit to NHS hospitals, but indirect
costs are important when considering the cost-benefit
analysis from a patient, health care provider, or societal
perspective.
Weaknesses of this study include the fact that the
completeness of data collection may have varied across
sites, despite standardised training and data collection
source documents designed to minimise omissions.
Although we deliberately selected a range of representative
vitreoretinal units, they may not be representative of all UK
vitreoretinal units, and extrapolation to other countries is
likely to be of limited use. At present vitreoretinal care is
provided by NHS hospitals, but the costs of undertaking
vitrectomy may differ if private providers enter the market,
although the HRG tariff they will receive from CCG would
remain the same. For reasons of commercial sensitivity
1.8 % of item costs were undisclosed and we had to esti-
mate these costs based on equivalent equipment costs
disclosed from other units. Out-of-theatre costs were esti-
mated based on accounting costs for patients undergoing
PPV for the same conditions, but they were not actually the
same patients, and this might introduce error. Likewise, the
overhead cost is an estimate, albeit one that is advocated by
the Department of Health and widely used.
This study provides data on the major cost drivers
influencing the direct cost of performing intermediate
complexity PPV in the NHS. It suggests that many hospi-
tals may not be fully reimbursed for PPV, and that the HRG
codes and tariffs could be refined to better match hospital
costs. Inaccurate coding also contributed to underpay-
ments. It may nonetheless be cost-effective for hospitals to
undertake additional PPVs for VMT, ERM and MH, as
units undertaking a sufficient volume of work can amortise
existing infrastructure. Although this research was set in
England, the methodology may provide a useful template
for other countries. Further research is needed to estimate
the real out-of-theatre costs and indirect costs of PPV.
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